With more and more people signing up for weight loss drugs, the potential side effects are starting to attract attention.

Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

The filmmaker’s candid post opens a conversation about health, stigma, and promising advances in diabetes and weight ...

Baron Fifth Avenue Growth Fund declined during the first quarter of 2025, underperforming its benchmark, the Russell 1000 ...

The global race for weight loss solutions has firmly arrived in India—bringing with it hope, hype, and a host of unanswered ...

While drugmakers battle over costs, MoveSmarter Health, a U.S. startup launched in Argentina, is sidestepping the fray with a ...

In this week’s S&P 500 healthcare earnings roundup, 21 of 24 companies beat earnings expectations, while three fell short. On the revenue front, seven missed Wa ...

Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025.

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

Kyle Richards’s daughter, Sophia Umansky, shared alarming footage of her hair loss after rapidly losing weight with the help ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...